Abstract 581P
Background
Afatinib is an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that is widely used to treatfor EGFR-mutated non-small cell lung cancer (NSCLC). The association between afatinib-related adverse events (AEs) and survival outcomes in patients with NSCLC has been rarely reported.
Methods
We retrospectively reviewed treatment-naȉive patients with NSCLC treated with afatinib for ≥1 month at Chang Gung Memorial Hospital. We analyzed the association between different types of AEs and clinical outcomes, including progression-free survival (PFS) and overall survival (OS).
Results
This study included 599 patients. The patients who experienced any grades of AEs had longer OS (median OS = 27.2 vs. 14.0 months, p = 0.019) than those who did not. As for PFS did not differ significantly between these two groups. Regarding the types of AE, the patients with either paronychia (median PFS =, 16.0 vs. 12.4 months, p = 0.011), skin lesions (median PFS =, 15.4 vs. 12.1 months, p = 0.042), or gastrointestinal (GI) symptoms, including nausea/vomiting (median PFS =, 18.8 vs. 14.3 months, p = 0.016), had experienced significantly better PFS than patients without these AEs. In addition, the patients with either paronychia (median OS =, 31.0 vs. 21.0 months, p < 0.001), skin lesions (median OS =, 29.3 vs. 20.9 months, p < 0.001), pruritus (median OS =, 31.6 vs. 24.7 months, p < 0.001), or mucositis/oral ulcers (median OS =, 30.2 vs. 25,5 months, p < 0.023) had showed better OS than patients without these AEs. After adjustment, the patients with experiencing paronychia and GI symptoms had favorable PFS, and those with paronychia, skin lesions, pruritus, or mucositis/oral ulcers had favorable OS.
Conclusions
Patients with NSCLC treated with patients undergoing afatinib and experiencing adverse events (AEs) had favorable survival PFS and OS. In addition, the associations between afatinib-related AEs and survival outcomes were type-dependent.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract